By Mill Chart
Last update: Nov 10, 2023
Our stock screener has spotted GENMAB A/S -SP ADR (NASDAQ:GMAB) as a growth stock which is not overvalued. NASDAQ:GMAB is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.
ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:GMAB, the assigned 8 reflects its growth potential:
ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:GMAB scores a 5 out of 10:
ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:GMAB scores a 8 out of 10:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:GMAB was assigned a score of 7 for profitability:
Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.
For an up to date full fundamental analysis you can check the fundamental report of GMAB
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
NASDAQ:GMAB (5/9/2025, 3:37:06 PM)
19.475
+0.05 (+0.28%)
Find more stocks in the Stock Screener
GENMAB A/S -SP ADR is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:GMAB showcases decent financial health and profitability, coupled with an attractive price.
Based on a technical and fundamental analysis of NASDAQ:GMAB we can say: GENMAB A/S -SP ADR (NASDAQ:GMAB), a strong growth stock, setting up for a breakout.
Peter Lynch, one of the most successful investors of all time, focused on growth stocks with strong fundamentals and a business model that’s easy to understand. Let’s analyze whether GENMAB A/S -SP ADR (NASDAQ:GMAB) fits his legendary investment approach.
GENMAB A/S -SP ADR was identified as a growth stock that isn't overvalued. NASDAQ:GMAB is excelling in various growth indicators while maintaining a solid financial footing.